Kaftrio* (elexacaftor/tezacaftor/ivacaftor) vs Trixacar (elexacaftor/tezacaftor/ivacaftor; ivacaftor)
Kaftrio* (elexacaftor/tezacaftor/ivacaftor) vs Trixacar (elexacaftor/tezacaftor/ivacaftor; ivacaftor)
Kaftrio (known as Trikafta in the United States) and Trixacar are both combination medications containing elexacaftor, tezacaftor, and ivacaftor, which are used to treat cystic fibrosis in individuals with specific genetic mutations. The primary difference between the two is that Trixacar comes with an additional supply of ivacaftor to be taken separately, allowing for a tailored dosage adjustment that may be required for some patients based on their specific needs or response to treatment. When deciding on the appropriate medication, it is crucial to consult with a healthcare professional who can evaluate the patient's genetic profile, clinical status, and potential drug interactions to determine the most suitable treatment option.
Difference between Kaftrio* and Trixacar
| Metric | Kaftrio* (elexacaftor/tezacaftor/ivacaftor) | Trixacar (elexacaftor/tezacaftor/ivacaftor; ivacaftor) |
|---|---|---|
| Generic name | Elexacaftor/tezacaftor/ivacaftor | Elexacaftor/tezacaftor/ivacaftor and ivacaftor |
| Indications | Cystic fibrosis in patients with at least one F508del mutation in the CFTR gene | Cystic fibrosis in patients with at least one F508del mutation in the CFTR gene |
| Mechanism of action | CFTR modulator therapy | CFTR modulator therapy |
| Brand names | Kaftrio | Trikafta |
| Administrative route | Oral | Oral |
| Side effects | Headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, increased liver enzymes, nasal congestion, increased blood creatinine phosphokinase, rhinorrhea, influenza, sinusitis, and increased bilirubin | Similar to Kaftrio, with the addition of potential drug interactions due to the extra ivacaftor dose |
| Contraindications | Use of certain drugs (e.g., strong CYP3A inhibitors), history of hypersensitivity to any of the components | Similar to Kaftrio, with considerations for the extra ivacaftor dose |
| Drug class | CFTR modulator | CFTR modulator |
| Manufacturer | Vertex Pharmaceuticals | Vertex Pharmaceuticals |
Efficacy
Efficacy of Kaftrio in Cystic Fibrosis
Kaftrio, known as Trikafta in the United States, is a combination medication that includes elexacaftor, tezacaftor, and ivacaftor. It has been approved for the treatment of cystic fibrosis (CF) in patients aged 12 years and older with at least one F508del mutation in the CFTR gene, which is the most common mutation causing CF. Clinical trials have demonstrated that Kaftrio significantly improves lung function, as measured by the percent predicted forced expiratory volume in one second (ppFEV1), in individuals with this genetic mutation.
The efficacy of Kaftrio was shown in a pivotal phase 3 trial, where patients treated with Kaftrio experienced a mean increase of approximately 10-14% in ppFEV1 compared to baseline, which was sustained over the 24-week treatment period. This improvement in lung function was accompanied by reductions in pulmonary exacerbations and improvements in body mass index (BMI), both of which are important indicators of health in CF patients.
Efficacy of Trixacar in Cystic Fibrosis
Trixacar, which is a brand name for the same combination of elexacaftor, tezacaftor, and ivacaftor, followed by ivacaftor taken separately, has also been evaluated for its efficacy in treating CF. The medication works by targeting the underlying cause of the disease, the defective CFTR protein, helping to correct its function and improve the transport of salts and fluids across cell membranes. This mechanism of action is crucial in alleviating the symptoms and progression of CF.
Trixacar has shown similar improvements in lung function, quality of life, and other clinical outcomes as Kaftrio, given that they contain the same active ingredients. The additional dose of ivacaftor in Trixacar is intended to further enhance the activity of the CFTR protein, providing an additional therapeutic benefit. Clinical studies have supported the use of this regimen in individuals with specific genetic mutations that are responsive to CFTR modulator therapy, leading to significant clinical improvements for patients with CF.
Regulatory Agency Approvals
Kaftrio*
-
European Medical Agency (EMA), European Union
Trixacar
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
ANMAT (ARG)
Access Kaftrio* or Trixacar today
If Kaftrio* or Trixacar are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us